Skip to main content
Evidence Snapshot

cGMP-dependent protein kinase 2

CHEMBL2896 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2896
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats cGMP-dependent protein kinase 2 as ChEMBL target CHEMBL2896, mapped to UniProt Q13237. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
cGMP-dependent protein kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2896
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q13237
cGMP-dependent protein kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why cGMP-dependent protein kinase 2 matters

As of 2026-09-14

cGMP-dependent protein kinase 2 is reviewed as cGMP-dependent protein kinase 2 (UniProt Q13237); the current evidence base includes 3 approved drugs, 1225 compounds, and 168 assays, with lead potency reaching pChEMBL 8.6.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 1225 compounds, and 168 assays for this target. The dominant activity type is KI. CHEMBL1990254 is the current potency anchor at pChEMBL 8.6.

Use CHEMBL1990254 as the tractability anchor when discussing potency (pChEMBL 8.6).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 8.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why cGMP-dependent protein kinase 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13237, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1225
Total Compounds
168
Total Assays
3
Approved Drugs
IC50: 19.0, KI: 520.0, KD: 121.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1990254
 8.6 Ki —
No preferred name
CHEMBL5278787
 8.6 IC50 —
No preferred name
CHEMBL494089
 8.5 Kd —
No preferred name
CHEMBL1976240
 8.4 Ki —
No preferred name
CHEMBL2001751
 8.4 Ki —

Approved Drugs

Structure Compound First Approval
MIDOSTAURIN
CHEMBL608533
 2017
RUXOLITINIB
CHEMBL1789941
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2896